Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 25 of 25 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
AXL positive	acute myeloid leukemia	sensitive	Bemcentinib	Phase I	Actionable	In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in complete response in 12.5% (1/8), partial response in 12.5% (1/8), and stable disease in 37.5% (3/8) of acute myeloid leukemia patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)).	detail...
AXL positive	myelodysplastic syndrome	sensitive	Bemcentinib	Phase I	Actionable	In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in stable disease in 100% (3/3) of myelodysplastic syndrome patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)).	detail...
AXL positive	Advanced Solid Tumor	predicted - sensitive	Enapotamab vedotin	Preclinical - Pdx	Actionable	In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066).	detail...
AXL positive	triple-receptor negative breast cancer	sensitive	20G7-D9	Preclinical - Pdx	Actionable	In a preclinical study, 20G7-D9 inhibited tumor growth in triple-negative breast cancer cell line xenograft models with high or moderate AXL expression and in AXL-expressing patient-derived xenograft (PDX) models (PMID: 27923843).	27923843
AXL positive	pancreatic cancer	sensitive	ADCT-601	Preclinical - Pdx	Actionable	In a preclinical study, ADCT-601 inhibited growth of an AXL-positive pancreatic cancer cell line in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 35086955).	35086955
AXL positive	esophageal cancer	sensitive	ADCT-601	Preclinical - Pdx	Actionable	In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955).	35086955
AXL positive	glioblastoma	sensitive	BMS-777607	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524).	26848524
AXL positive	lung non-small cell carcinoma	unknown	INCB081776	Preclinical - Cell line xenograft	Actionable	In a preclinical study, INCB081776 inhibited Axl phosphorylation in tumor, enhanced anti-tumor immune response, inhibited tumor growth in immunocompetent, but not immunodeficient mouse models of non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 3759).	detail...
AXL positive	triple-receptor negative breast cancer	sensitive	ADCT-601	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive triple-negative breast cancer cell line in culture and resulted in complete responses in 4/10, partial responses in 5/10, and tumor-free survival in 4/10 cell line xenograft models (PMID: 35086955).	35086955
AXL positive	renal cell carcinoma	sensitive	ADCT-601	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955).	35086955
AXL positive	lung non-small cell carcinoma	sensitive	ADCT-601	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ADCT-601 inhibited growth of an AXL-positive non-small cell lung cancer cell line in culture and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 35086955).	35086955
AXL positive	Ewing sarcoma	sensitive	Bemcentinib	Preclinical - Cell culture	Actionable	In a preclinical study, Bemcentinib (BGB-324) inhibited growth of Ewing sarcoma cell lines positive for Axl expression in culture (PMID: 25528764).	25528764
AXL positive	triple-receptor negative breast cancer	sensitive	Dubermatinib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a triple-receptor negative breast cancer cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334).	27671334
AXL positive	lung non-small cell carcinoma	sensitive	Dubermatinib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334).	27671334
AXL positive	head and neck squamous cell carcinoma	sensitive	Dubermatinib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334).	27671334
AXL positive	triple-receptor negative breast cancer	sensitive	Bemcentinib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an AXL-expressing triple-receptor negative breast cancer cell line demonstrated greater sensitivity to the combination of Bemcentinib (BGB-324) and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334).	27671334
AXL positive	lung non-small cell carcinoma	sensitive	Bemcentinib + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, an AXL-expressing non-small cell lung carcinoma cell line demonstrated greater sensitivity to the combination of BGB-324 and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334).	27671334
AXL positive	chronic myeloid leukemia	sensitive	AXL CAR-T cells	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AXL CAR-T cells led to induced death of AXL-expressing chronic myeloid leukemia (CML) cells and did not induce death of AXL-negative CML cells in culture (PMID: 29497107).	29497107
AXL positive	glioblastoma	sensitive	ADCT-601	Preclinical - Cell culture	Actionable	In a preclinical study, ADCT-601 inhibited growth of an AXL-positive glioblastoma cell line in culture (PMID: 35086955).	35086955
AXL positive	lung adenocarcinoma	sensitive	ADCT-601	Preclinical - Cell culture	Actionable	In a preclinical study, ADCT-601 inhibited growth of an AXL-positive lung adenocarcinoma cell line in culture (PMID: 35086955).	35086955
AXL positive	ovary adenocarcinoma	sensitive	ADCT-601	Preclinical - Cell culture	Actionable	In a preclinical study, ADCT-601 inhibited growth of an AXL-positive ovarian adenocarcinoma cell line in culture (PMID: 35086955).	35086955
AXL positive	Advanced Solid Tumor	sensitive	ER-851	Preclinical - Cell culture	Actionable	In a preclinical study, ER-851 decreased viability of transformed cells expressing AXL in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 36279567).	36279567
AXL positive	head and neck squamous cell carcinoma	sensitive	Bemcentinib	Preclinical	Actionable	In a preclinical study, Bemcentinib (BGB-324) inhibited proliferation and invasion of head and neck squamous cell carcinoma cell lines positive for Axl expression in culture (PMID: 25767293).	25767293
AXL positive	head and neck squamous cell carcinoma	sensitive	Bemcentinib + Cetuximab	Preclinical	Actionable	In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293).	25767293
AXL positive	breast cancer	sensitive	Bemcentinib	Preclinical	Actionable	In a preclinical study, Bemcentinib (BGB-324) inhibited tumor growth and metastasis in xenograft models of Axl-positive breast cancer cell lines, resulting in prolonged survival (PMID: 20145120).	20145120

Showing 1 to 25 of 25 entries

Filter rows:

Profile Name	AXL positive
Gene Variant Detail	AXL positive (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting